Berg kicks off cancer metabolism study
FRAMINGHAM, Mass.—Pharmaceutical company Berg has announced a first-of-its-kind Phase 1b clinical trial to be conducted with Weill Cornell Medical College, Palo Alto Medical Foundation and the University of Texas M.D. Anderson Cancer Center. The trial will investigate BPM 31510 (IV continuous infusion) as a cancer therapy for solid tumors. The compound targets the cellular machinery that controls cancer cell metabolism to make them behave like healthy cells, and is the first treatment in Berg’s pipeline discovered and developed by the company’s Interrogative Biology platform. Weill Cornell will enroll between 300 and 400 cancer patients with solid tumors for the study, and the clinical program will identify the molecular and metabolic fingerprint of each patient through the analysis of multi-omic tissue samples in real time. One trial arm will treat patients with a cycle of BPM 31510 followed by chemotherapy to see if efficacy increases and chemotherapy side effects decrease.